Previous 10 | Next 10 |
Summary Viking Therapeutics has a compound similar to Madrigal Pharmaceuticals', only a few years later in development. Madrigal is now nearing its endgame, and Viking is falling behind. Madrigal's success, if that happens, will have a negative impact on Viking Therapeutics. ...
Madrigal will have a key catalytic event in Q4. This is the data from the ~900 patient subpart H population of biopsy-proven NASH patients. Earlier trial data and current lows make it a screaming buy before this binary event. Madrigal ( MDGL ) is down again substanti...
Madrigal Pharmaceuticals press release ( NASDAQ: MDGL ): Q2 GAAP EPS of -$4.14 misses by $0.46 . As of June 30, 2022, Madrigal had cash, cash equivalents and marketable securities of $211.8 million, compared to $270.3 million at December 31, 2021. For further det...
Madrigal remains on track to announce topline data from the Phase 3 MAESTRO-NASH biopsy study in the fourth quarter CONSHOHOCKEN, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel ther...
B Riley Securities has downgraded the clinical-stage biotech Madrigal Pharmaceuticals ( NASDAQ: MDGL ) to Neutral from Buy, questioning the potential of a late-stage study for the company’s NASH candidate resmetirom to generate positive results this year. NASH, also...
Gainers: MyMD Pharmaceuticals ( MYMD ) +23% . Clovis Oncology ( CLVS ) +22% . iRhythm Technologies ( IRTC ) +22% . Acer Therapeutics ( ACER ) +15% . Atreca ( BCEL ) +12% . Losers: RAPT Therapeutics ( RAPT ) -9% ...
Which of the healthcare producers of Diagnostic Solutions is now a better buy to help build your portfolio’s near-term capital value? Near-term only, repetition provides long term. Here find out what the best-informed, big-$ investors now think is likely to happen (good and bad...
Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...
Late-breaking data from the double-blind portion of the noninvasive Phase 3 MAESTRO NAFLD-1 study show resmetirom to be safe and well-tolerated and to reduce liver fat, fibrosis measures on FibroScan and MRE, and liver enzymes, as well as multiple atherogenic lipids In NASH pati...
The following slide deck was published by Madrigal Pharmaceuticals, Inc. in conjunction with this event. For further details see: Madrigal Pharmaceuticals (MDGL) Investor Presentation - Slideshow
News, Short Squeeze, Breakout and More Instantly...
Madrigal Pharmaceuticals Inc. Company Name:
MDGL Stock Symbol:
NASDAQ Market:
Madrigal Pharmaceuticals Inc. Website:
CONSHOHOCKEN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2024 financial results on Wednesday, August 7, 2024, prior to the open of the U.S. financial markets. Following the announcement...
2024-06-30 12:02:00 ET Madrigal Pharmaceuticals (NASDAQ: MDGL) is at a moment of great opportunity, and there's a decent chance that its shareholders will feel good about their investments over the next few years. After commercializing its first medicine, which treats a condition no...
2024-06-16 12:05:00 ET If you're eyeing an investment in Madrigal Pharmaceuticals (NASDAQ: MDGL) , now's the time to imagine a representative of Eli Lilly (NYSE: LLY) interrupting your train of thought by saying something along the lines of, "Not so fast." While the biotech ...